PeriVision raises CHF 2.4M to advance AI- and VR-based eye testing

Every year, millions risk losing their eyesight due to glaucoma and other diseases that are often diagnosed too late. Traditional eye tests remain time-consuming, resource-heavy, and out of reach for many patients. PeriVision SA, a Swiss medtech and AI spin-off from the University of Bern, is addressing this gap with its platform VisionOne, which uses commercial VR headsets and AI algorithms to provide faster, more reliable, and patient-friendly visual field testing.

The Medtech company PeriVision has secured CHF 2.4 million (USD 3 million) in seed funding to expand its platform with new VR-based tests for retinal diseases, advanced AI insights, and integrations designed to deliver a complete solution for eye clinics, optometry practices, and biopharma partners.

PeriVision’s technology is already certified in major markets, including the EU, US, and UK, and its first product is on the market. With the new funding, the company plans to broaden its clinical offering and extend its international reach in 2025. Over the past three years, PeriVision has also earned recognition through grants, awards, and accelerator programs, including the EIT Health Wild Card, Innosuisse project grants, the Venture Leaders Medtech program, and the Biopôle Vanguard Accelerator.

The Medtech company has been ranked among the Top100 Swiss Startups, won Venture Kick, and participated in Venture Leaders Medtech.


PeriVision team